Tags : BREEZE-AD1

Eli Lilly Reports Results of Olumiant (baricitinib) in P-III BREEZE-AD1

Shots: The two P-III study BREEZE-AD1 and BREEZE-AD2 involves assessing of baricitinib vs PBO in patients with moderate-to-severe AD The two P-III study resulted in meeting 1EPs @16 wks. with no venous thromboembolic events (VTEs), major adverse cardiovascular events (MACE) & deaths rates Olumiant (baricitinib, 2mg) indicated for moderate-to-severe RA who have had an inadequate […]Read More

Eli Lilly’s Olumiant (baricitinib) Receives FDA’s Fast Track Designation for

Shots: The FDA’s designation is based on P-II study results assessing Baricitinib in patients with SLE, presented at European Congress of Rheumatology 2018 Lilly is also evaluating baricitinib’s two doses in P-III SLE trials and for moderate-to -severe atopic dermatitis, with its expected results in H1’19 Olumiant (baricitinib) 2mg is an inhibitor of janus kinase, further blocking […]Read More